已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 1856: Synergistic combination of PROTACs degrading oncogenic proteins: In vitro studies and formulating a long-acting injectable for in vivo testing in lung tumor-bearing mice

体内 体外 癌症研究 医学 癌症 生物 内科学 生物化学 生物技术
作者
Akanksha Patel,Mukti Vats,Ketan Patel
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 1856-1856
标识
DOI:10.1158/1538-7445.am2025-1856
摘要

Introduction: Lung cancer remains a leading cause of cancer-related mortality worldwide, with accountability of more than 85% of cases of non-small cell lung cancer (NSCLC). Current therapies, such as EGFR inhibitors (e.g., erlotinib, gefitinib), face significant challenges, including severe side effects, drug resistance, and financial burdens, leading to patient noncompliance. In recent years, Protein-Targeting Chimeras (PROTACs), a class of protein degraders, is a groundbreaking strategy that degrades, rather than merely inhibits, targets proteins. This work investigates a combination of PROTACs degrading key oncogenic proteins of lung cancer. BRD4 degrading PROTAC (BPRO) and an EGFR degrading PROTAC (EPRO) were combined to simultaneously degrade BRD4 and EGFR to suppress c-MYC, EGFR and K-RAS, offering therapeutic potential for NSCLC with diverse genetic profiles. Objectives: Our study objectives include (a) evaluating BE-PRO synergism in various NSCLC cell line i.e. wild-type EGFR (H460 cells), EGFR TKI-sensitive (PC9 cells), and EGFR TKI-resistant (H4006/GR) cells; (b) assessing anticancer efficacy of BE-PRO in 2D and 3D NSCLC models; and (c) optimizing a self-injectable biodegradable subcutaneous depot formulation (BERD) for sustained delivery; (d) to analyze the in vivo anticancer efficacy of BERD in NSCLC cells tumor xenograft model. Methods: In vitro assays - IC50 and combination index (CI), invasion assay, clonogenic assay, and 3D spheroids growth were carried out to identify the synergistic ratio of BPRO and EPRO in different NSCLC cell lines. 3D-cell viability and apoptosis were studied using Cell Titer-Glo® 3D and Live/Dead Cell imaging assays. Further, depot formulation was developed using a biodegradable polymer and tested using a subcutaneous tissue-mimicking phantom using IVIS imaging. To determine the in vivo efficacy of BERD, a subcutaneously engrafted HCC827 cells xenograft model has been developed, and currently, we are measuring tumor growth using ultrasound and vernier caliper methods. Results: The combination index and cytotoxicity interaction graph demonstrated of BPRO and EPRO (CI = 0.25±0.026 in H460; 0.151±0.047 in PC9, 0.693±0.013 in H4006/GR) and significant inhibition of invasion and clonogenic activity. The combination showed minimal toxicity in healthy cells, HEK 293, and lung fibroblast. In 3D spheroids, BE-PRO achieved ∼74.5% and ∼53.3% growth inhibition under chronic and acute dose regimens, respectively. BERD ensured sustained drug release over 72 hrs, with minimal precipitation and reduced initial burst effects compared to the individual drug solution. Conclusion: A sustained-release combination of BRD4 and EGFR degrading PROTACs could be a promising approach, tackling key oncogenic drives while minimizing dosing frequency and off-target toxicities. Citation Format: Akanksha Patel, Mukti Vats, Ketan Patel. Synergistic combination of PROTACs degrading oncogenic proteins: In vitro studies and formulating a long-acting injectable for in vivo testing in lung tumor-bearing mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1856.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉卿发布了新的文献求助10
刚刚
1秒前
fu完成签到,获得积分20
2秒前
褚华健完成签到,获得积分10
2秒前
傻狗完成签到,获得积分20
2秒前
almost发布了新的文献求助10
2秒前
Akim的应助被夏侯乌采纳,获得10
2秒前
105完成签到,获得积分10
2秒前
4秒前
大丑橘粑粑柑公主完成签到,获得积分10
5秒前
Spark完成签到,获得积分10
5秒前
ForTune发布了新的文献求助10
7秒前
简简单单完成签到,获得积分10
7秒前
8秒前
zjwzcxy发布了新的文献求助10
8秒前
VDC的应助被初景采纳,获得30
8秒前
何yezi完成签到 ,获得积分10
8秒前
9秒前
天青111完成签到,获得积分10
9秒前
11秒前
11秒前
宿雨发布了新的文献求助10
12秒前
sss完成签到,获得积分10
12秒前
高高的毒娘完成签到 ,获得积分10
13秒前
14秒前
15秒前
夏侯乌发布了新的文献求助10
15秒前
ddl30发布了新的文献求助10
15秒前
passerby完成签到 ,获得积分10
16秒前
FF发布了新的文献求助10
16秒前
16秒前
哈哈哈完成签到 ,获得积分10
17秒前
ysss0831完成签到 ,获得积分0
17秒前
18秒前
19秒前
zjwzcxy完成签到,获得积分10
21秒前
23秒前
almost发布了新的文献求助10
23秒前
24秒前
bbd发布了新的文献求助10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184686
求助须知:如何正确求助?哪些是违规求助? 9573640
关于积分的说明 21832630
捐赠科研通 7782020
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558513
邀请新用户注册赠送积分活动 2481010